Acrux Limited (ARUXF)
OTHER OTC:ARUXF
ARUXF Stock Chart & Stats
$0.01
<$0.01(41.59%)
At close: 4:00 PM EST
$0.01
<$0.01(41.59%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.05
Previous CloseN/A
Volume500.00
Average Volume (3M)5.33K
Market Cap
$3.39M
Enterprise Value$7.62M
Total Cash (Recent Filing)$863.00K
Total Debt (Recent Filing)$3.63M
Price to Earnings (P/E)9.3
Beta1.19
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding410,608,520
10 Day Avg. Volume6,100
30 Day Avg. Volume5,333
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.51
Price to Sales (P/S)4.73
P/FCF Ratio-1.03
Enterprise Value/Market Cap2.25
Enterprise Value/Revenue6.40
Enterprise Value/Gross Profit-6.82
Enterprise Value/Ebitda-0.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Licensing / Royalty Business ModelAcrux's partner-led, royalty and milestone model is capital-light and scalable over time. By leveraging partners' commercial and regulatory capabilities instead of building a large salesforce, the company can convert development wins into recurring, high-margin royalty streams and one‑off milestone receipts when partners successfully commercialize products.
Proprietary Transdermal IPAcrux's concentration on transdermal and topical delivery technologies constitutes a durable technical moat. Ownership and management of specialized IP enable out‑licensing opportunities, protect market position versus generic entrants, and underpin long‑term revenue via license fees and royalties tied to pharmaceutical partners' commercialization.
Improving Revenue And Gross MarginRecent substantial revenue growth and a marked gross margin improvement indicate strengthening commercial traction with partners and a shift toward higher-margin licensing receipts. If sustained, these trends support durable operating leverage: revenue growth that converts to outsized gross profit can fund development and reduce reliance on external financing over the medium term.
Bears Say
High Financial LeverageA debt-to-equity ratio above 3x materially limits financial flexibility. Elevated leverage increases interest and refinancing risk, constrains ability to invest in development or pursue new partnerships, and magnifies downside if partner milestones or royalty receipts are delayed, making the company more vulnerable during market stress.
Persistent Negative ProfitabilityOngoing net losses and negative EBIT margins show that current operations and financing are not profitable, eroding retained equity and deterring reinvestment. Negative ROE reflects inability to generate returns for shareholders, implying the company will likely need continued external funding or successful milestone monetization to reach sustainable profitability.
Negative Operating And Free Cash FlowNegative operating and free cash flows indicate the business is not self-funding and depends on financing, milestones, or partner receipts to cover operations. With free cash flow closely aligned to net losses, liquidity is constrained and the company faces renewed refinancing or covenant risk unless it secures sustained royalty inflows or reduces cash burn.
Acrux News
ARUXF FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest stock price was <$0.01 and its highest was $0.05 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is $3.39M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Aug 21, 2026 which is in 146 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Feb 24, 2026. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Annually dividend of $0.063 which represents an annual dividend yield of N/A. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 410,608,520 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in ARUXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-211.88%
Trailing 12-Months
Asset Growth
-34.57%
Trailing 12-Months
Company Description
Acrux Limited
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was incorporated in 1998 and is based in West Melbourne, Australia.
Technical Analysis
Clinuvel Pharmaceuticals
―
Starpharma Holdings Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―
Ownership Overview
Options Prices
Currently, No data available
---